Dr Rebecca Dent
Medical Oncologist
- National Cancer Center Singapore
Singapore
Dr Rebecca Dent has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
AstraZeneca, Eisai, Genentech, Lilly, Merck, Novartis, Pfizer and Roche.
Programmes developed by Dr Rebecca Dent
Oncology
Update From ASCO 2022 – Selected LBAs
COR2ED brings you an update on the late breaker plenary sessions from ASCO 2022
Experts
Dr Rebecca Dent, Prof. Chiara Cremolini, Asst. Prof. Hans Lee, Prof. Jonathan Trent-
7 MIN
-
May 2022
Interactive e-learning
Oncology
The Role of PARP Inhibition in Clinical Practice
Experts
Prof. Jonathan A. Ledermann, Dr Rebecca Dent, Dr Robert L. Coleman, Prof. Eric Pujade-Lauraine-
60 MIN
-
Sep 2021
Publication
Oncology
Moving from PARP Inhibition to Targeting DNA Repair and DDR in Cancer Therapy
Experts
Dr Judith Balmaña, Dr Rebecca Dent, Prof. Simon Boulton, Prof. Sibylle Loibl, Prof. Eric Pujade-Lauraine, Prof. Charlie Gourley, Dr Violeta Serra, Prof. Jonathan A. Ledermann-
Downloadable
Resources -
10 MIN
-
Sep 2021
Oncology
An Experts’ Forum in Tokyo and Singapore on DDR and PARP inhibition
Experts
Prof. Keiichi Fujiwara, Prof. Simon Boulton, Dr Shinji Ohno, Dr Rebecca Dent, Prof. Charlie Gourley-
Downloadable
Resources -
60 MIN
-
Sep 2021